Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.66 |
| ▸ | TACR1 | P25103 | 17/20 | 0.60 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631404 | 0.94 | TACR3 (0.71) | TACR3TACR1CCR2 | |
| SCHEMBL631395 | 0.92 | TACR3 (0.76) | TACR3TACR1CCR2 | |
| SCHEMBL631626 | 0.92 | TACR3 (0.69) | TACR3TACR1CCR2 | |
| SCHEMBL632152 | 0.91 | TACR3 (0.70) | TACR3TACR1CCR2 | |
| SCHEMBL631544 | 0.90 | TACR3 (0.66) | TACR3TACR1CCR2 | |
| SCHEMBL631336 | 0.89 | TACR3 (0.66) | TACR3TACR1CCR2 | |
| SCHEMBL631708 | 0.88 | TACR3 (0.64) | TACR3TACR1CCR2 | |
| SCHEMBL631174 | 0.88 | TACR3 (0.64) | TACR3TACR1CCR2 | |
| SCHEMBL5002837 | 0.88 | TACR3 (0.50) | TACR3TACR1CCR2 | |
| SCHEMBL632756 | 0.86 | TACR3 (0.69) | TACR3TACR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | claimed |
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | claimed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | claimed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | claimed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| CN-101622259-B | spiropiperidine derivatives as NK3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-01 | — | — | CN | disclosed |
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | ADRB3, KCNK3, KCND3 | TACR3 28/4885TACR1 6/4885CCR2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.